➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
McKesson
Colorcon
Merck

Last Updated: April 15, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for PHA-793887

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PHA-793887?

PHA-793887 is an investigational drug.

There have been 31 clinical trials for PHA-793887. The most recent clinical trial was a Phase 3 trial, which was initiated on February 4th 2020.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Endocrine System Diseases, and Dwarfism, Pituitary. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.

There are twenty-one US patents protecting this investigational drug and one hundred and forty-eight international patents.

Recent Clinical Trials for PHA-793887
TitleSponsorPhase
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPharvaris Netherlands B.V.Phase 2
Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPhase 4
The Benefit of Bermekimab in Patients With Systemic SclerosisHellenic Institute for the Study of SepsisPhase 2

See all PHA-793887 clinical trials

Clinical Trial Summary for PHA-793887

Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887

See all PHA-793887 clinical trials

US Patents for PHA-793887

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PHA-793887   Start Trial Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA)   Start Trial
PHA-793887   Start Trial Inhibitors of cyclin-dependent kinase 7 (CDK7) Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
PHA-793887   Start Trial Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
PHA-793887   Start Trial Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA)   Start Trial
PHA-793887   Start Trial Maturation of hepatocyte-like cells derived from human pluripotent stem cells Takara Bio Europe AB (Gothenburg, SE)   Start Trial
PHA-793887   Start Trial Inhibitors of cyclin-dependent kinase 7 (CDK7) Syros Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PHA-793887

Drugname Country Document Number Estimated Expiration Related US Patent
PHA-793887 Australia AU2014337044 2033-10-18   Start Trial
PHA-793887 Australia AU2019200372 2033-10-18   Start Trial
PHA-793887 Canada CA2927920 2033-10-18   Start Trial
PHA-793887 China CN105849099 2033-10-18   Start Trial
PHA-793887 European Patent Office EP3057956 2033-10-18   Start Trial
PHA-793887 Japan JP2016533379 2033-10-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
McKesson
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.